Saturday and Sunday - CLOSED
Contact Us For Help
New York, W2 3XE
Our highest priority is to improve diagnostic and therapeutic approaches to human health. CTC liquid biopsy offeres detection and analysis of important, but rare, cells associated with disease.
Frontier will provide researchers and oncologists with access to unparalleled precision in molecular characterization.
Our CELLTRAK® technology provides a simple, minimally invasive liquid biopsy that captures, isolates and enumerates circulating tumor cells (CTCs) for valuable oncologic information to make informed clinical decisions.
The first and only clinical trial seeking FDA-clearance, a blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body.
A “liquid biopsy” that can be used at any time during a patient’s course of disease. Performed at our Head Laboratories in Germany. This trial will be processed using the CELLSTRAK® Circulating Tumor Cell System
As an adjunct to standard methods of monitoring, the CELLTRAK® CTC Test provides:
An early assessment of patient prognosis Detection of changes in prognosis at any time The most accurate assessment of prognosis in cases where CTC and imaging are discordant in patients with metastatic breast cancer, and in cases where CTC and PSA are discordant in patients with metastatic prostate cancer
Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23(7):1420-1430.
de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14:6302-6309.
Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26(19):3213-3221.
CEO &Bio Chemist
Frontier Board Member, Principal designer of trials & data revirew.
Frontier Board Member & Lead Researcher on trail
Better Diagnostics Saves Lives
The CELLTRAK® CTC trial is a simple, actionable blood test that helps oncologists assess the prognosis of patients with metastatic breast, prostate* , or colorectal cancer.
Early detection can improve survival rates by up to 90%. Schedule your test today!
© 2025 Cancer Testing.
Designed and Developed by Attors Technologies. All Rights Reserved.